Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration‐Resistant Prostate Cancer Patients: A Sub‐Analysis From the ENABLE Study

• DOI: 10.1002/pros.24897
• Publication Date: 2025-04-05T08:50:44Z
• Authors: Takehiko Okamura; Kouji Izumi; Satoshi Kurokawa; Takashi Shima; Yuki Kato; Koji Mita; Manabu Kamiyama; Shogo Inoue; Seiji Hoshi; Nobumichi Tanaka; Yuko Yoshio; Hideki Enokida; Ippei Chikazawa; Noriyasu Kawai; Kohei Hashimoto; Takashi Fukagai; Kazuyoshi Shigehara; Shizuko Takahara; Atsushi Mizokami
• Keywords: Enzalutamide; Prednisolone

ABSTRACT Background Clinical trials rarely focus on elder patients with castration‐resistant prostate cancer (CRPC), and data the outcomes of second‐generation androgen receptor signaling inhibitors (ARSIs) remain limited. Methods The ENABLE study for was an investigator‐initiated, multicenter, randomized controlled trial conducted in Japan to compare enzalutamide (ENZ) abiraterone plus prednisolone (ABI). This sub‐analysis performed evaluate efficacy safety profiles between aged ≥ 75 (older) < years (younger), then ENZ ABI arms older younger cohort separately. Results arm included 41 51 patients, while 36 56 patients. No significant differences survival endpoints were observed Median time prostate‐specific antigen (PSA) progression (TTPP) 15.2 months 21.2 (HR 0.84, 95% CI 0.53–1.33, p = 0.4647). overall (OS) 33.7 37.8 0.80, 0.50–1.29, 0.3651). Among ( n 107), had a TTPP compared 10.1 OS 44.7 0.1506 0.9321, respectively). Any grade 3 adverse events 47 (61%) 11 (14%) 73 (68%) 18 (17%) respectively. found any or 0.3487 0.6885, Conclusions ARSIs demonstrated similar both may be more suitable option due its higher PSA response rate. Trial Registration registered University Hospital Medical Information Network (UMIN) Center under identifier UMIN000015529.